Head-To-Head Review: Protagenic Therapeutics (PTIX) versus Its Peers

Protagenic Therapeutics (NASDAQ:PTIX) is one of 1,000 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Protagenic Therapeutics to related businesses based on the strength of its earnings, profitability, institutional ownership, risk, analyst recommendations, valuation and dividends.

Profitability

This table compares Protagenic Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protagenic Therapeutics	N/A	-101.81%	-82.18%
Protagenic Therapeutics Competitors	-2,459.06%	-249.83%	-30.60%

Volatility and Risk

Protagenic Therapeutics has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Protagenic Therapeutics’ peers have a beta of 1.09, indicating that their average share price is 9% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Protagenic Therapeutics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagenic Therapeutics	0	0	0	0	N/A
Protagenic Therapeutics Competitors	6394	18743	44698	918	2.57

As a group, “Pharmaceutical preparations” companies have a potential upside of 78.62%. Given Protagenic Therapeutics’ peers higher probable upside, analysts clearly believe Protagenic Therapeutics has less favorable growth aspects than its peers.

Valuation and Earnings

This table compares Protagenic Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Protagenic Therapeutics	N/A	-$5.00 million	-1.08
Protagenic Therapeutics Competitors	$1.68 billion	$146.16 million	-1.64

Protagenic Therapeutics’ peers have higher revenue and earnings than Protagenic Therapeutics. Protagenic Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

8.0% of Protagenic Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 37.0% of Protagenic Therapeutics shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Protagenic Therapeutics peers beat Protagenic Therapeutics on 6 of the 10 factors compared.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.